KR20200014736A - 니라파립 조성물 - Google Patents

니라파립 조성물 Download PDF

Info

Publication number
KR20200014736A
KR20200014736A KR1020197031668A KR20197031668A KR20200014736A KR 20200014736 A KR20200014736 A KR 20200014736A KR 1020197031668 A KR1020197031668 A KR 1020197031668A KR 20197031668 A KR20197031668 A KR 20197031668A KR 20200014736 A KR20200014736 A KR 20200014736A
Authority
KR
South Korea
Prior art keywords
composition
phenyl
carboxamide
indazol
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031668A
Other languages
English (en)
Korean (ko)
Inventor
조지 우
존 차버
Original Assignee
테사로, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63676949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200014736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테사로, 인코포레이티드 filed Critical 테사로, 인코포레이티드
Publication of KR20200014736A publication Critical patent/KR20200014736A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197031668A 2017-03-27 2018-03-27 니라파립 조성물 Ceased KR20200014736A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
US62/477,411 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Publications (1)

Publication Number Publication Date
KR20200014736A true KR20200014736A (ko) 2020-02-11

Family

ID=63676949

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031668A Ceased KR20200014736A (ko) 2017-03-27 2018-03-27 니라파립 조성물

Country Status (14)

Country Link
US (3) US11091459B2 (cg-RX-API-DMAC10.html)
EP (1) EP3600314A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020512350A (cg-RX-API-DMAC10.html)
KR (1) KR20200014736A (cg-RX-API-DMAC10.html)
CN (1) CN110944638A (cg-RX-API-DMAC10.html)
AU (2) AU2018246214B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019020211A2 (cg-RX-API-DMAC10.html)
CA (1) CA3058375C (cg-RX-API-DMAC10.html)
EA (1) EA201992177A1 (cg-RX-API-DMAC10.html)
IL (1) IL269630A (cg-RX-API-DMAC10.html)
MX (1) MX2019011496A (cg-RX-API-DMAC10.html)
SG (1) SG11201909011PA (cg-RX-API-DMAC10.html)
TW (1) TWI761476B (cg-RX-API-DMAC10.html)
WO (1) WO2018183354A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
JP2023524794A (ja) 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ.ベー. アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
US20250352534A1 (en) 2022-02-15 2025-11-20 Tesaro, Inc. Use of Niraparib for the Treatment of Brain Cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
JP2026517228A (ja) 2023-05-17 2026-05-28 テサロ, インコーポレイテッド がんの治療におけるポリadpリボースポリメラーゼ(parp)阻害剤の新規使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
MX2010004028A (es) * 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
EP2240466B1 (en) * 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク. 多環系化合物の新規形態
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9191894B2 (en) * 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
EP3424909A1 (en) 2014-01-05 2019-01-09 Washington University A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor
WO2015164161A1 (en) 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
JP6648040B2 (ja) 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
HRP20240136T1 (hr) * 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019067978A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. POLYTHERAPIES FOR THE TREATMENT OF CANCER
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
BR112020015909A2 (pt) 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
US12297184B2 (en) * 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CA3087392A1 (en) * 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate

Also Published As

Publication number Publication date
TW201840315A (zh) 2018-11-16
SG11201909011PA (en) 2019-10-30
CA3058375C (en) 2025-05-06
AU2021245223A1 (en) 2021-11-04
BR112019020211A2 (pt) 2020-04-22
CN110944638A (zh) 2020-03-31
TWI761476B (zh) 2022-04-21
IL269630A (en) 2019-11-28
EP3600314A1 (en) 2020-02-05
EA201992177A1 (ru) 2020-02-25
US11091459B2 (en) 2021-08-17
CA3058375A1 (en) 2018-10-04
US20230416223A1 (en) 2023-12-28
AU2018246214A1 (en) 2019-11-07
WO2018183354A1 (en) 2018-10-04
US20210403448A1 (en) 2021-12-30
US20200017462A1 (en) 2020-01-16
MX2019011496A (es) 2020-01-23
JP2020512350A (ja) 2020-04-23
AU2018246214B2 (en) 2021-07-08
US11673877B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
US11673877B2 (en) Niraparib compositions
US11730725B2 (en) Niraparib formulations
JP2019112436A (ja) ルキソリチニブの徐放性投薬形態
KR20100093057A (ko) 리카르바제핀 아세테이트를 포함하는 경구 투여형
JP2016053094A (ja) 口腔内分散性製剤
KR20150126345A (ko) 마이봄 기능부전의 치료제
PT1958617E (pt) Composições farmacêuticas contendo fumarato de quetiapina
CN114867469A (zh) 包含氨基甲酸酯化合物的口服药物组合物及其制备方法
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
JP7084950B2 (ja) 非拍動性持続放出ベタヒスチン経口固形組成物
US20060034911A1 (en) New oral immediated release dosage form
EP2976067B1 (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
US20220257611A1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
KR102936624B1 (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
EP3581180B1 (en) Antimicrobial compositions with effervescent agents
ES2773756A2 (es) Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua
WO2012039691A2 (en) Synergic effect
KR20240040407A (ko) 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물
RU2452476C2 (ru) Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
WO2025079089A1 (en) Pharmaceutical composition of cabozantinib
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
BRPI0713709A2 (pt) composição farmacéutica oral, processo de preparação de uma composição, e, método para usar composição

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210326

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20210402

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210811

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220216

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210811

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I